GENFIT S A/ADR (GNFT) Expected to Post Earnings of -$0.72 Per Share

Wall Street brokerages predict that GENFIT S A/ADR (NASDAQ:GNFT) will report ($0.72) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for GENFIT S A/ADR’s earnings, with the lowest EPS estimate coming in at ($0.73) and the highest estimate coming in at ($0.70). The business is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that GENFIT S A/ADR will report full year earnings of ($2.91) per share for the current year, with EPS estimates ranging from ($3.25) to ($2.49). For the next year, analysts forecast that the firm will post earnings of ($2.85) per share, with EPS estimates ranging from ($3.76) to ($1.75). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for GENFIT S A/ADR.

GNFT has been the subject of a number of research analyst reports. Roth Capital reaffirmed a “buy” rating on shares of GENFIT S A/ADR in a research report on Tuesday, April 23rd. HC Wainwright cut their price objective on shares of GENFIT S A/ADR to $72.00 and set a “buy” rating for the company in a research report on Monday, April 22nd. Leerink Swann initiated coverage on shares of GENFIT S A/ADR in a research report on Wednesday, April 24th. They set an “outperform” rating and a $25.47 price objective for the company. Svb Leerink initiated coverage on shares of GENFIT S A/ADR in a research report on Wednesday, April 24th. They set an “outperform” rating and a $58.00 price objective for the company. Finally, Barclays initiated coverage on shares of GENFIT S A/ADR in a research report on Monday, April 22nd. They set an “overweight” rating and a $55.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average target price of $52.62.

Large investors have recently bought and sold shares of the stock. Morgan Stanley acquired a new position in GENFIT S A/ADR in the first quarter worth about $206,000. BlueCrest Capital Management Ltd acquired a new position in GENFIT S A/ADR in the first quarter worth about $240,000. New York State Common Retirement Fund acquired a new position in GENFIT S A/ADR in the first quarter worth about $267,000. One68 Global Capital LLC acquired a new position in GENFIT S A/ADR in the first quarter worth about $270,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in GENFIT S A/ADR in the first quarter worth about $449,000. 1.04% of the stock is owned by hedge funds and other institutional investors.

Shares of GNFT traded up $0.26 during trading hours on Thursday, reaching $23.60. 12,545 shares of the company traded hands, compared to its average volume of 152,357. GENFIT S A/ADR has a 1-year low of $20.81 and a 1-year high of $26.25.

About GENFIT S A/ADR

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Read More: Marijuana Stocks

Get a free copy of the Zacks research report on GENFIT S A/ADR (GNFT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.